Halozyme Therapeutics Inc... (HALO)
NASDAQ: HALO
· Real-Time Price · USD
66.50
0.63 (0.96%)
At close: May 12, 2025, 3:59 PM
66.35
-0.23%
After-hours: May 12, 2025, 06:50 PM EDT
Halozyme Therapeutics Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|
| Product Revenue | 303.49M | 300.85M | 108.61M | 135.19M | 123.01M | 60.05M |
| Product Revenue Growth | +0.88% | +177.00% | -19.66% | +9.90% | +104.86% | n/a |
| Bulk rHuPH20 Revenue | 86.33M | 115.44M | 191.03M | 104.22M | 55.99M | 66.05M |
| Bulk rHuPH20 Revenue Growth | -25.21% | -39.57% | +83.29% | +86.16% | -15.23% | n/a |
| Collaborative Agreements Revenue | 140.84M | 80.53M | 360.48M | 203.9M | 88.6M | 69.9M |
| Collaborative Agreements Revenue Growth | +74.88% | -77.66% | +76.79% | +130.15% | +26.75% | n/a |
| Royalty Revenue | 570.99M | 447.87M | 10M | 50M | 15M | n/a |
| Royalty Revenue Growth | +27.49% | +4378.65% | -80.00% | +233.33% | n/a | n/a |
| Sales-based milestone Revenue | 30M | n/a | n/a | n/a | n/a | n/a |
| Sales-based milestone Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a |
| Upfront Fees Revenue | 27M | n/a | n/a | n/a | n/a | n/a |
| Upfront Fees Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 42.25M | 41.24M | 35.71M | 35.13M | 37.61M | 35.27M | 38.95M | 37.36M | 37.75M | 34.47M | 57.48M | 13.83M | 13.77M | 13.17M | 12.32M | 11.06M | 10.43M | 11.7M | 10.97M | 12.63M | 23.93M | 17.98M | 17.34M | 18.01M | 18.03M | 14.86M | 14.35M | 13.56M | 14.77M | 13.33M | 13.1M | 12.62M | 12.23M | 11.6M | 11.22M | 10.81M | 10.59M | 10.23M | 9.81M | 9.4M |
| Selling, General, and Administrative Revenue Growth | +2.44% | +15.49% | +1.64% | -6.58% | +6.63% | -9.45% | +4.26% | -1.04% | +9.52% | -40.03% | +315.47% | +0.44% | +4.59% | +6.88% | +11.41% | +6.06% | -10.90% | +6.62% | -13.12% | -47.21% | +33.09% | +3.70% | -3.71% | -0.14% | +21.31% | +3.56% | +5.88% | -8.23% | +10.82% | +1.74% | +3.85% | +3.17% | +5.41% | +3.37% | +3.84% | +2.05% | +3.55% | +4.20% | +4.42% | n/a |
| Research and Development Revenue | 20.44M | 18.46M | 21.04M | 19.11M | 21.34M | 17.32M | 19.73M | 17.98M | 22.57M | 16.7M | 15.48M | 11.85M | 10.11M | 8.49M | 8.07M | 9.01M | 7.38M | 7.75M | 8.95M | 10.16M | 45.11M | 30.45M | 33.91M | 31.33M | 36.65M | 35.54M | 40.09M | 37.98M | 41.38M | 33.99M | 38.34M | 36.94M | 41.35M | 33.86M | 35.53M | 40.1M | 27.75M | 27.61M | 21.2M | 16.68M |
| Research and Development Revenue Growth | +10.74% | -12.26% | +10.08% | -10.43% | +23.18% | -12.20% | +9.72% | -20.33% | +35.09% | +7.89% | +30.63% | +17.26% | +19.11% | +5.17% | -10.43% | +22.07% | -4.74% | -13.45% | -11.88% | -77.48% | +48.12% | -10.19% | +8.24% | -14.52% | +3.12% | -11.34% | +5.56% | -8.22% | +21.72% | -11.34% | +3.80% | -10.67% | +22.11% | -4.69% | -11.40% | +44.53% | +0.49% | +30.27% | +27.04% | n/a |